Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 14 | 2025 | 302 | 3.040 |
Why?
|
| Magnetic Resonance Imaging | 12 | 2020 | 1310 | 1.530 |
Why?
|
| Diabetes Mellitus, Type 2 | 10 | 2026 | 1477 | 1.290 |
Why?
|
| Brain | 10 | 2020 | 949 | 1.000 |
Why?
|
| Dementia | 6 | 2026 | 247 | 0.920 |
Why?
|
| Aged | 41 | 2026 | 10637 | 0.900 |
Why?
|
| Artificial Intelligence | 3 | 2013 | 64 | 0.800 |
Why?
|
| Risk Assessment | 3 | 2018 | 1469 | 0.740 |
Why?
|
| Female | 46 | 2026 | 20375 | 0.670 |
Why?
|
| Diet Therapy | 2 | 2020 | 15 | 0.670 |
Why?
|
| Humans | 56 | 2026 | 32969 | 0.640 |
Why?
|
| DNA Methylation | 3 | 2025 | 145 | 0.610 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 52 | 0.600 |
Why?
|
| Aging | 8 | 2025 | 955 | 0.600 |
Why?
|
| Databases, Factual | 2 | 2018 | 369 | 0.600 |
Why?
|
| Postmenopause | 6 | 2026 | 427 | 0.590 |
Why?
|
| Aged, 80 and over | 22 | 2025 | 4065 | 0.570 |
Why?
|
| Exercise Therapy | 2 | 2020 | 282 | 0.550 |
Why?
|
| Oxygen | 2 | 2009 | 144 | 0.540 |
Why?
|
| Nerve Net | 2 | 2016 | 125 | 0.530 |
Why?
|
| Metabolomics | 3 | 2017 | 64 | 0.520 |
Why?
|
| Cognition | 8 | 2026 | 553 | 0.490 |
Why?
|
| Body Weight | 2 | 2020 | 302 | 0.480 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 125 | 0.470 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 126 | 0.460 |
Why?
|
| Male | 29 | 2026 | 19754 | 0.450 |
Why?
|
| Cardiovascular Diseases | 5 | 2024 | 1152 | 0.430 |
Why?
|
| Middle Aged | 23 | 2026 | 12203 | 0.420 |
Why?
|
| Cerebrovascular Circulation | 3 | 2017 | 96 | 0.410 |
Why?
|
| Diabetic Retinopathy | 1 | 2014 | 73 | 0.410 |
Why?
|
| Brain Mapping | 5 | 2011 | 179 | 0.410 |
Why?
|
| Apolipoprotein E4 | 3 | 2024 | 57 | 0.400 |
Why?
|
| Women's Health | 6 | 2024 | 235 | 0.400 |
Why?
|
| Algorithms | 7 | 2020 | 517 | 0.390 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2011 | 225 | 0.380 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 2287 | 0.350 |
Why?
|
| Risk Factors | 12 | 2026 | 4001 | 0.350 |
Why?
|
| Coronary Disease | 3 | 2024 | 217 | 0.340 |
Why?
|
| Cognition Disorders | 4 | 2019 | 370 | 0.330 |
Why?
|
| Air Pollution | 2 | 2024 | 17 | 0.320 |
Why?
|
| Particulate Matter | 3 | 2024 | 28 | 0.320 |
Why?
|
| Estrogens | 1 | 2011 | 169 | 0.310 |
Why?
|
| Models, Theoretical | 2 | 2016 | 138 | 0.310 |
Why?
|
| Life Style | 3 | 2026 | 409 | 0.300 |
Why?
|
| tau Proteins | 3 | 2026 | 39 | 0.300 |
Why?
|
| Longitudinal Studies | 7 | 2026 | 780 | 0.300 |
Why?
|
| Incidence | 7 | 2026 | 1246 | 0.290 |
Why?
|
| Behavior Therapy | 2 | 2020 | 103 | 0.290 |
Why?
|
| Hemodynamics | 1 | 2009 | 162 | 0.280 |
Why?
|
| Hormone Replacement Therapy | 2 | 2019 | 89 | 0.260 |
Why?
|
| Epigenesis, Genetic | 2 | 2025 | 108 | 0.260 |
Why?
|
| Models, Biological | 1 | 2009 | 392 | 0.250 |
Why?
|
| Aldosterone | 2 | 2017 | 27 | 0.250 |
Why?
|
| Exercise | 4 | 2021 | 688 | 0.250 |
Why?
|
| Memory Disorders | 2 | 2018 | 54 | 0.240 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 551 | 0.240 |
Why?
|
| Renin | 2 | 2017 | 109 | 0.240 |
Why?
|
| Software | 1 | 2006 | 128 | 0.240 |
Why?
|
| Proteomics | 2 | 2024 | 102 | 0.230 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 388 | 0.230 |
Why?
|
| Adult | 14 | 2026 | 9586 | 0.230 |
Why?
|
| Cohort Studies | 8 | 2026 | 1852 | 0.230 |
Why?
|
| Breast Feeding | 1 | 2026 | 47 | 0.230 |
Why?
|
| Automobile Driving | 1 | 2025 | 26 | 0.230 |
Why?
|
| Prediabetic State | 1 | 2026 | 74 | 0.230 |
Why?
|
| Environmental Exposure | 3 | 2024 | 89 | 0.230 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2016 | 138 | 0.220 |
Why?
|
| Multifactorial Inheritance | 1 | 2024 | 23 | 0.210 |
Why?
|
| Wrist | 2 | 2021 | 48 | 0.210 |
Why?
|
| Magnetics | 1 | 2004 | 5 | 0.210 |
Why?
|
| Tomography | 1 | 2004 | 5 | 0.210 |
Why?
|
| Lipid Metabolism | 1 | 2024 | 105 | 0.210 |
Why?
|
| Air Pollutants | 1 | 2024 | 23 | 0.210 |
Why?
|
| Antidepressive Agents | 1 | 2024 | 74 | 0.210 |
Why?
|
| Weight Loss | 2 | 2017 | 462 | 0.200 |
Why?
|
| Insulin Resistance | 2 | 2017 | 469 | 0.200 |
Why?
|
| Nutrition Surveys | 2 | 2026 | 151 | 0.200 |
Why?
|
| Computer Simulation | 4 | 2009 | 224 | 0.200 |
Why?
|
| Inflammation | 4 | 2024 | 542 | 0.190 |
Why?
|
| African Americans | 4 | 2017 | 1425 | 0.190 |
Why?
|
| Baltimore | 3 | 2018 | 50 | 0.190 |
Why?
|
| Phenotype | 1 | 2024 | 644 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 837 | 0.180 |
Why?
|
| Blood Pressure | 2 | 2024 | 867 | 0.180 |
Why?
|
| Young Adult | 8 | 2021 | 2738 | 0.170 |
Why?
|
| Logistic Models | 2 | 2013 | 783 | 0.170 |
Why?
|
| Prospective Studies | 6 | 2026 | 2338 | 0.170 |
Why?
|
| United States | 7 | 2026 | 4133 | 0.170 |
Why?
|
| Depression | 1 | 2024 | 448 | 0.170 |
Why?
|
| Coronary Artery Disease | 1 | 2024 | 416 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 72 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2018 | 770 | 0.160 |
Why?
|
| Brain Ischemia | 2 | 2012 | 148 | 0.160 |
Why?
|
| Health Care Costs | 1 | 2020 | 122 | 0.150 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 424 | 0.150 |
Why?
|
| C-Reactive Protein | 2 | 2019 | 240 | 0.150 |
Why?
|
| Medicare | 1 | 2020 | 213 | 0.150 |
Why?
|
| Lipoproteins, LDL | 1 | 2019 | 80 | 0.150 |
Why?
|
| Disease Progression | 2 | 2018 | 594 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2020 | 182 | 0.140 |
Why?
|
| Auditory Cortex | 2 | 2009 | 21 | 0.140 |
Why?
|
| Visual Cortex | 2 | 2009 | 34 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2019 | 183 | 0.140 |
Why?
|
| Blood | 1 | 2018 | 14 | 0.140 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 22 | 0.140 |
Why?
|
| Mass Screening | 1 | 2020 | 268 | 0.140 |
Why?
|
| Atherosclerosis | 1 | 2024 | 801 | 0.140 |
Why?
|
| Models, Psychological | 1 | 2018 | 26 | 0.140 |
Why?
|
| Metabolome | 1 | 2018 | 39 | 0.140 |
Why?
|
| Lipids | 1 | 2019 | 230 | 0.130 |
Why?
|
| Auditory Perception | 2 | 2009 | 80 | 0.130 |
Why?
|
| Cholesterol | 1 | 2019 | 255 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2017 | 1582 | 0.130 |
Why?
|
| Visual Perception | 2 | 2009 | 116 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 19 | 0.130 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 18 | 0.130 |
Why?
|
| alpha-Macroglobulins | 1 | 2016 | 2 | 0.130 |
Why?
|
| Phospholipids | 1 | 2017 | 29 | 0.130 |
Why?
|
| Neoplasms | 1 | 2024 | 762 | 0.130 |
Why?
|
| Health Education | 1 | 2018 | 162 | 0.130 |
Why?
|
| Anthropometry | 1 | 2016 | 84 | 0.120 |
Why?
|
| Muscle Proteins | 1 | 2016 | 64 | 0.120 |
Why?
|
| Waist Circumference | 1 | 2016 | 92 | 0.120 |
Why?
|
| Glucose | 1 | 2017 | 188 | 0.120 |
Why?
|
| Demography | 1 | 2016 | 110 | 0.120 |
Why?
|
| Leptin | 1 | 2016 | 73 | 0.120 |
Why?
|
| Radiography | 2 | 2016 | 386 | 0.120 |
Why?
|
| Adiponectin | 1 | 2016 | 103 | 0.120 |
Why?
|
| Cholesterol, HDL | 1 | 2016 | 178 | 0.120 |
Why?
|
| Insulin-Secreting Cells | 1 | 2016 | 53 | 0.120 |
Why?
|
| Triglycerides | 1 | 2016 | 229 | 0.120 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 72 | 0.120 |
Why?
|
| Diet | 1 | 2017 | 393 | 0.110 |
Why?
|
| Stroke | 2 | 2017 | 610 | 0.110 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2016 | 91 | 0.110 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2014 | 9 | 0.110 |
Why?
|
| Renin-Angiotensin System | 1 | 2016 | 178 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 30 | 0.110 |
Why?
|
| Apolipoproteins E | 3 | 2019 | 87 | 0.110 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 195 | 0.110 |
Why?
|
| Prognosis | 1 | 2018 | 1547 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2016 | 495 | 0.100 |
Why?
|
| ROC Curve | 1 | 2014 | 169 | 0.100 |
Why?
|
| Time Factors | 1 | 2018 | 2195 | 0.100 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 68 | 0.090 |
Why?
|
| Neuropsychological Tests | 3 | 2026 | 363 | 0.090 |
Why?
|
| Retinal Vessels | 1 | 2012 | 26 | 0.090 |
Why?
|
| Retinal Diseases | 1 | 2012 | 26 | 0.090 |
Why?
|
| Phosphorylation | 2 | 2026 | 226 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 445 | 0.090 |
Why?
|
| Horses | 1 | 2011 | 15 | 0.090 |
Why?
|
| Attention | 2 | 2009 | 82 | 0.080 |
Why?
|
| Image Enhancement | 1 | 2011 | 70 | 0.080 |
Why?
|
| Brain Diseases | 1 | 2011 | 38 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2011 | 112 | 0.080 |
Why?
|
| Models, Neurological | 1 | 2011 | 119 | 0.080 |
Why?
|
| Obesity | 1 | 2017 | 1179 | 0.080 |
Why?
|
| Energy Metabolism | 2 | 2021 | 163 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 682 | 0.070 |
Why?
|
| Perceptual Disorders | 1 | 2009 | 7 | 0.070 |
Why?
|
| Membrane Transport Proteins | 2 | 2019 | 33 | 0.070 |
Why?
|
| Organ Size | 3 | 2016 | 220 | 0.070 |
Why?
|
| Activities of Daily Living | 2 | 2021 | 258 | 0.070 |
Why?
|
| Normal Distribution | 1 | 2008 | 12 | 0.070 |
Why?
|
| Neural Inhibition | 1 | 2008 | 27 | 0.070 |
Why?
|
| Bayes Theorem | 1 | 2008 | 85 | 0.070 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2007 | 29 | 0.070 |
Why?
|
| Risk | 2 | 2019 | 316 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 134 | 0.060 |
Why?
|
| Statistics as Topic | 1 | 2006 | 104 | 0.060 |
Why?
|
| Metformin | 1 | 2026 | 25 | 0.060 |
Why?
|
| Adolescent | 4 | 2020 | 3643 | 0.060 |
Why?
|
| Hypoglycemic Agents | 1 | 2026 | 183 | 0.050 |
Why?
|
| Heterozygote | 1 | 2024 | 61 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2024 | 59 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2024 | 94 | 0.050 |
Why?
|
| Electromagnetic Fields | 1 | 2004 | 28 | 0.050 |
Why?
|
| Artifacts | 1 | 2004 | 42 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2017 | 909 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2024 | 486 | 0.050 |
Why?
|
| Mortality | 1 | 2024 | 125 | 0.050 |
Why?
|
| Pregnancy | 1 | 2026 | 981 | 0.050 |
Why?
|
| Signal Transduction | 1 | 2024 | 689 | 0.040 |
Why?
|
| Medicare Part A | 1 | 2020 | 5 | 0.040 |
Why?
|
| Wrist Joint | 1 | 2021 | 60 | 0.040 |
Why?
|
| Medicare Part B | 1 | 2020 | 5 | 0.040 |
Why?
|
| Medicare Part D | 1 | 2020 | 10 | 0.040 |
Why?
|
| Eligibility Determination | 1 | 2020 | 18 | 0.040 |
Why?
|
| Health Services | 1 | 2020 | 39 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 92 | 0.040 |
Why?
|
| Counseling | 1 | 2020 | 98 | 0.040 |
Why?
|
| Health Expenditures | 1 | 2020 | 68 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2020 | 238 | 0.040 |
Why?
|
| Animals | 1 | 2011 | 7599 | 0.040 |
Why?
|
| Apolipoprotein C-I | 1 | 2019 | 4 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2019 | 12 | 0.040 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 37 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2020 | 265 | 0.040 |
Why?
|
| Forecasting | 1 | 2019 | 143 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 21 | 0.030 |
Why?
|
| Problem Solving | 1 | 2018 | 26 | 0.030 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2017 | 2 | 0.030 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2017 | 7 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 894 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 495 | 0.030 |
Why?
|
| Sphingomyelins | 1 | 2017 | 7 | 0.030 |
Why?
|
| Acoustic Stimulation | 2 | 2009 | 125 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 18 | 0.030 |
Why?
|
| Diet Surveys | 1 | 2017 | 55 | 0.030 |
Why?
|
| Phosphatidylcholines | 1 | 2017 | 21 | 0.030 |
Why?
|
| Sleep | 1 | 2018 | 89 | 0.030 |
Why?
|
| Hypertension | 1 | 2024 | 983 | 0.030 |
Why?
|
| Thiazoles | 1 | 2017 | 27 | 0.030 |
Why?
|
| Calcineurin | 1 | 2016 | 3 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 39 | 0.030 |
Why?
|
| Amino Acids | 1 | 2017 | 46 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 499 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1002 | 0.030 |
Why?
|
| Fasting | 1 | 2017 | 94 | 0.030 |
Why?
|
| Morbidity | 1 | 2017 | 101 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 240 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 185 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2016 | 76 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2018 | 197 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2016 | 142 | 0.030 |
Why?
|
| Knee Prosthesis | 1 | 2016 | 17 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 334 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 265 | 0.030 |
Why?
|
| Health Status | 1 | 2018 | 403 | 0.030 |
Why?
|
| Osteoarthritis, Knee | 1 | 2016 | 82 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 765 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 1068 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 684 | 0.030 |
Why?
|
| Knee Joint | 1 | 2016 | 143 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 260 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 475 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2017 | 410 | 0.030 |
Why?
|
| Neurons | 1 | 2016 | 417 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2017 | 487 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 541 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 976 | 0.020 |
Why?
|
| Reference Values | 1 | 2011 | 238 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 460 | 0.020 |
Why?
|
| Photic Stimulation | 1 | 2009 | 159 | 0.020 |
Why?
|
| Parietal Lobe | 1 | 2008 | 13 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2016 | 3460 | 0.020 |
Why?
|
| Functional Laterality | 1 | 2008 | 56 | 0.020 |
Why?
|
| Neural Pathways | 1 | 2008 | 95 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2008 | 80 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2006 | 54 | 0.020 |
Why?
|
| Movement | 1 | 2006 | 51 | 0.020 |
Why?
|
| Fingers | 1 | 2006 | 69 | 0.020 |
Why?
|